This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Matloff, E. T. Articles by Peshkin, B. N. Search for Related Content PubMed PubMed Citation Articles by Matloff, E. T. Articles by Peshkin, B. N. Social Bookmarking                            What's this?

What Would You Do? Specialists’ Perspectives on Cancer Genetic Testing, Prophylactic Surgery, and Insurance Discrimination

From the Department of Genetics, Yale School of Medicine, and Cancer Genetic Counseling Shared Resources, Yale Cancer Center, Yale University, New Haven, CT.

Address reprint requests to Ellen T. Matloff, MS, Cancer Genetic Counseling, Yale Cancer Center, Yale School of Medicine, 333 Cedar St, Box 208028, New Haven, CT 06520-8028; email ellen.matloff@ yale.edu.

PURPOSE: To examine what cancer genetics specialists predict they would do personally if they were at 50% risk of carrying a mutation that predisposes to hereditary breast/ovarian cancer (BRCA1/BRCA2) and hereditary nonpolyposis colon cancer (HNPCC).

METHODS: Questionnaire survey of the membership of the National Society of Genetic Counselors (NSGC) Special Interest Group (SIG) in Cancer.

RESULTS: Of the 296 active members of the NSGC Cancer-SIG surveyed, 163 (55%) responded. Eighty-five percent predicted that if they had a 50% risk of carrying a BRCA1/BRCA2 mutation, they would pursue genetic testing. If they tested positive for a mutation at age 35, 25% predicted they would pursue prophylactic bilateral mastectomies and 68%, prophylactic oophorectomy. Ninety-one percent of respondents believe they would pursue genetic testing for HNPCC, and 17% would elect prophylactic colectomy; 54%, prophylactic hysterectomy; and 52%, prophylactic oophorectomy if they tested positive for a mutation. The majority (68%) would not bill their insurance companies for genetic testing because of fear of discrimination, and 26% would use an alias when undergoing testing. Fifty-seven percent of counselors would seek professional psychologic support to help them cope with the results of testing.

CONCLUSION: A large percentage of cancer genetic counseling providers predicted they would opt for prophylactic surgery at a young age if they carried a BRCA or HNPCC mutation, and most would seek professional psychologic assistance when undergoing testing. More than half of respondents would not bill their insurance companies for genetic testing, largely because of fear of genetic discrimination. The vast majority of those providers most familiar with cancer genetic testing and its associated medical, psychologic, and legal implications would still pursue genetic testing.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. J. Geier, T. M. Mulvey, and J. N. Weitzel Clinical Cancer Genetics Remains a Specialized Area: How Do I Get There From Here? ASCO Educational Book, January 1, 2009; 2009(1): 644 - 651. [Abstract] [Full Text] [PDF]

				K. L. Hudson Prohibiting Genetic Discrimination N. Engl. J. Med., May 17, 2007; 356(20): 2021 - 2023. [Full Text] [PDF]

				T. Krahn Where are we going with preimplantation genetic diagnosis? Can. Med. Assoc. J., May 8, 2007; 176(10): 1445 - 1446. [Full Text] [PDF]

				K. Anderson, J. S. Jacobson, D. F. Heitjan, J. G. Zivin, D. Hershman, A. I. Neugut, and V. R. Grann Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med, March 21, 2006; 144(6): 397 - 406. [Abstract] [Full Text] [PDF]

				K G Fulda and K Lykens Ethical issues in predictive genetic testing: a public health perspective. J. Med. Ethics, March 1, 2006; 32(3): 143 - 147. [Abstract] [Full Text] [PDF]

				R. E. Ensenauer, V. V. Michels, and S. S. Reinke Genetic Testing: Practical, Ethical, and Counseling Considerations Mayo Clin. Proc., January 1, 2005; 80(1): 63 - 73. [Abstract] [PDF]

				R. Sifri, S. Gangadharappa, and L. S. Acheson Identifying and Testing for Hereditary Susceptibility to Common Cancers CA Cancer J Clin, November 1, 2004; 54(6): 309 - 326. [Abstract] [Full Text] [PDF]

				C. C. Hook, E. P. DiMagno, and A. Tefferi Primer on Medical Genomics Part XIII: Ethical and Regulatory Issues Mayo Clin. Proc., May 1, 2004; 79(5): 645 - 650. [Abstract] [PDF]

				S. Gray and O. I. Olopade Direct-to-Consumer Marketing of Genetic Tests for Cancer: Buyer Beware J. Clin. Oncol., September 1, 2003; 21(17): 3191 - 3193. [Full Text] [PDF]

				S. Morgan, J. Hurley, F. Miller, and M. Giacomini Predictive genetic tests and health system costs Can. Med. Assoc. J., April 15, 2003; 168(8): 989 - 991. [Full Text] [PDF]

				H. T. Lynch and A. de la Chapelle Hereditary Colorectal Cancer N. Engl. J. Med., March 6, 2003; 348(10): 919 - 932. [Full Text] [PDF]

				P. M. Calvert and H. Frucht The Genetics of Colorectal Cancer Ann Intern Med, October 1, 2002; 137(7): 603 - 612. [Abstract] [Full Text] [PDF]

				E. A. Peterson, K. J. Milliron, K. E. Lewis, S. D. Goold, and S. D. Merajver Health Insurance and Discrimination Concerns and BRCA1/2 Testing in a Clinic Population Cancer Epidemiol. Biomarkers Prev., January 1, 2002; 11(1): 79 - 87. [Abstract] [Full Text]

				M. Stefanek, L. Hartmann, and W. Nelson Risk-Reduction Mastectomy: Clinical Issues and Research Needs J Natl Cancer Inst, September 5, 2001; 93(17): 1297 - 1297. [Abstract] [Full Text] [PDF]

				H. T. Lynch and J. Lynch Lynch Syndrome: Genetics, Natural History, Genetic Counseling, and Prevention J. Clin. Oncol., November 1, 2000; 18(90001): 19s - 31. [Abstract] [Full Text] [PDF]